These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 38426040)
1. Cost-effectiveness of screening for amblyopia among kindergarten children in China. Gu YT; Shi B; Li DL; Zhang TT; Wang P; Jiang J; Pan CW Prev Med Rep; 2024 Mar; 39():102662. PubMed ID: 38426040 [TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of orthoptic screening in kindergarten: a Markov model based on data from Germany. König HH; Barry JC Pediatrics; 2004 Feb; 113(2):e95-108. PubMed ID: 14754978 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Universal School- and Community-Based Vision Testing Strategies to Detect Amblyopia in Children in Ontario, Canada. Asare AO; Maurer D; Wong AMF; Saunders N; Ungar WJ JAMA Netw Open; 2023 Jan; 6(1):e2249384. PubMed ID: 36598785 [TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of treatment for amblyopia: an analysis based on a probabilistic Markov model. König HH; Barry JC Br J Ophthalmol; 2004 May; 88(5):606-12. PubMed ID: 15090409 [TBL] [Abstract][Full Text] [Related]
5. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model. Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant Kong W; Yang X; Shu Y; Li S; Song B; Yang K Front Public Health; 2023; 11():1118307. PubMed ID: 36926178 [TBL] [Abstract][Full Text] [Related]
7. The potential cost-effectiveness of amblyopia screening programs. Rein DB; Wittenborn JS; Zhang X; Song M; Saaddine JB; J Pediatr Ophthalmol Strabismus; 2012; 49(3):146-55; quiz 145, 156. PubMed ID: 21877675 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of vaccination against COVID-19 in China. Zhou H; Ding N; Han X; Zhang H; Liu Z; Jia X; Yu J; Zhang W Front Public Health; 2023; 11():1037556. PubMed ID: 36960359 [TBL] [Abstract][Full Text] [Related]
9. Radiofrequency Catheter Ablation Versus Cryoballoon Ablation in the Treatment of Paroxysmal Atrial Fibrillation: A Cost-effectiveness Analysis in China. Sun XR; He SN; Lin ZY; Zhang L; Wang YJ; Zeng LJ; Shi L; Xuan JW; Tian Y; Yang XC; Liu XP Clin Ther; 2019 Jan; 41(1):78-91. PubMed ID: 30559005 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States. Guzauskas GF; Garbett S; Zhou Z; Spencer SJ; Smith HS; Hao J; Hassen D; Snyder SR; Graves JA; Peterson JF; Williams MS; Veenstra DL JAMA Netw Open; 2020 Oct; 3(10):e2022874. PubMed ID: 33119106 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial. Xin W; Ding H; Fang Q; Zheng X; Tong Y; Xu G; Yang G BMJ Open; 2020 Dec; 10(12):e038867. PubMed ID: 33371020 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China. Li W; Wan L BMJ Open; 2023 Sep; 13(9):e074245. PubMed ID: 37751954 [TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States. Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476 [TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China. Guan H; Sheng Y; Guo W; Han S; Shi L Adv Ther; 2019 May; 36(5):1114-1125. PubMed ID: 30900201 [TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service. Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China. Yao Y; Zhang R; An T; Zhao X; Zhang J ESC Heart Fail; 2020 Dec; 7(6):3582-3592. PubMed ID: 33107212 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer. Le V; Zhong L; Narsipur N; Hays E; Tran DK; Rosario K; Wilson L J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243 [No Abstract] [Full Text] [Related]
18. Cost-effectiveness of a hypothetical cell or gene therapy cure for sickle cell disease. Salcedo J; Bulovic J; Young CM Sci Rep; 2021 May; 11(1):10838. PubMed ID: 34035408 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of proton beam therapy for treatment decision making in paranasal sinus and nasal cavity cancers in China. Li G; Qiu B; Huang YX; Doyen J; Bondiau PY; Benezery K; Xia YF; Qian CN BMC Cancer; 2020 Jun; 20(1):599. PubMed ID: 32590957 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of imatinib versus dasatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia when combined with conventional chemotherapy in China. Chen M; Liu L; Zhang L; Lin Y; Lu X; Yang H; Ni J BMC Health Serv Res; 2023 Jun; 23(1):652. PubMed ID: 37331932 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]